2-(2-ethoxyphenyl)-8-oxo-9-phenyl-7H-purine-6-carboxamide

You're asking about **2-(2-ethoxyphenyl)-8-oxo-9-phenyl-7H-purine-6-carboxamide**, also known as **A-802645**. This compound is a potent and selective **inhibitor of phosphodiesterase 10A (PDE10A)**.

**PDE10A** is an enzyme that plays a critical role in the regulation of intracellular cyclic adenosine monophosphate (cAMP) levels, particularly in the brain.

**Here's why A-802645 is important for research:**

* **Understanding PDE10A function:** A-802645 has been instrumental in studying the role of PDE10A in various brain functions. By inhibiting PDE10A, researchers can observe the effects of increased cAMP levels in specific brain regions. This helps them understand how PDE10A contributes to neuronal signaling, learning, memory, and other cognitive processes.
* **Potential therapeutic applications:** A-802645 has shown promise as a potential treatment for conditions such as **schizophrenia**, **Parkinson's disease**, **Huntington's disease**, and **Alzheimer's disease**. These conditions are all characterized by disruptions in brain function related to neuronal signaling and plasticity.
* **Drug development:** A-802645 has served as a lead compound for the development of new drugs targeting PDE10A. By understanding the structure-activity relationship of A-802645, scientists can design improved PDE10A inhibitors with greater potency, selectivity, and pharmacokinetic properties.

**Research using A-802645 has yielded significant insights into the role of PDE10A and its potential as a therapeutic target. However, it's crucial to note that A-802645 is not yet approved for clinical use, and ongoing research is needed to establish its efficacy and safety for treating specific conditions.**